 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12345678910111213...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Early [ 18 F]FDG PET/CT response evaluation after a single dose of anti-EGFR therapy as a predictive biomarker for treatment benefit in patients with advanced colorectal cancer. (Hall A; Poster Bd #: 239) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2645;
P1/2
Selection of patients with left-sided RASwt/BRAFwt mCRC successfully identifies the majority (91%) of patients with clinical benefit from anti-EGFR monotherapy. For mCRC patients with inconclusive mutational screens early [ 18 F]FDG PET/CT evaluation may have clinical value to predict treatment benefit.
- Fruzaqla (fruquintinib) / Takeda
Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study. (Hall A; Poster Bd #: 230) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2636;
P2
PFS was significantly prolonged and ORR was improved in mCRC pts treated with Fru plus Cap as first-line maintenance treatment. This trial is ongoing and updated data will be presented in the future.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study. (Hall A; Poster Bd #: 222) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2628;
P2
Treatment with a combination of encorafenib and cetuximab is effective and well tolerated in Chinese patients with BRAF V600E mutant mCRC, resulting in a significantly longer PFS than standard therapies. These results are consistent with those previously reported in the BEACON study.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Real-world use of anti-EGFR therapy in metastatic colorectal cancer. (Hall A; Poster Bd #: 215) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2621;
Based on results from the Flatiron Health database, use of anti-EGFR therapy is enriched among patients with biomarker-based indications for treatment. Notably, anti-EGFR therapy was employed in only 56.6% of patients with RAS and RAF wildtype, left-sided mCRC, with decreased use observed from 2013 to 2023.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: First effectiveness data of the European multi-centric, multi-national, non-interventional study (Hall A; Poster Bd #: 214) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2620;
P=N/A
Despite the older study population and less ECOG PS 0 patients as compared to the pivotal study, the observed treatment effectiveness and safety profile are consistent with data from the BEACON CRC study. The recruitment of this study is ongoing and future analysis of the study will include an additional analysis of subgroups, effectiveness and QoL.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Efficacy of FOLFIRI plus bevacizumab versus FOLFIRI plus cetuximab in RAS-mutant metastatic colorectal cancer: Final update on patients with RAS-mutant metastatic colorectal cancer treated in FIRE-3. (Hall A; Poster Bd #: 213) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2619;
P3
While cetuximab notably is not effective in RASmut mCRC, this randomized comparison does not provide an indication for superior efficacy of bevacizumab in the first-line treatment of this patient group. Trial identification number: NCT00433927 [clinicaltrials.gov]
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Prognostic impact of HER family expressions for metastatic colorectal cancer (mCRC): SCRUM-Japan MONSTAR-SCREEN-2 and CALGB/SWOG 80405 trial (Alliance) international collaboration. (Hall A; Poster Bd #: 211) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2617;
P3
These insights may contribute to the development of more efficacious treatment methodologies according to HER family transcriptome expression profiles. ClinicalTrials.gov Identifier: NCT00265850.
- Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, evorpacept (ALX148) / ALX Oncology
Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC). (Hall A; Poster Bd #: 193) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2600;
P2
Further dose optimization of ECP is needed to establish a RD in the refractory MSS CRC population. While initial activity was seen, at the DLs evaluated, criteria for study termination were met.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of RAS wild-type (WT) metastatic colorectal cancer (mCRC): Pooled analysis of the randomized trials FIRE-1, FIRE-3, XELAVIRI, and PanaMa. (Hall A; Poster Bd #: 192) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2599;
CMS were confirmed as prognostic biomarkers and might contain predictive information for the choice of anti-EGFR or anti-VEGF antibodies in RAS WT mCRC. Prospective validation remains mandatory.
- QTX3034 / Quanta Therap
A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRAS G12D mutation. (Hall A; Poster Bd #: 311a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2143;
P1
To further optimize the recommended dose, patients will be randomized between two dose levels in the pancreatic cancer cohort. QTX3034 plus cetuximab will be explored following identification of a recommended combination dose in patients with CRC.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical and molecular characterization of AXL in colorectal cancer: CALGB (Alliance)/SWOG 80405 and real-world data. (Hall A; Poster Bd #: 290) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2116;
P3
AXL-H confers worse OS/PFS on first-line chemotherapy, with a more pronounced effect in KRASwt CRC. This data supports evaluation of AXL as a prognostic marker and potential therapeutic target in CRC.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Expression of metabolic genes associated with changes in brain structure across the lifespan affects patients (pts) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance). (Hall A; Poster Bd #: 289) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2115;
P3
Notably, APOE and DACH1 have been recently reported to play a role in CRC where APOE overexpression has been associated with aggressive biological behavior whereas DACH1 has been shown to suppress CRC cell growth and invasion. Our results support this evidence and suggest that further investigation into the role of APOE and DACH1 in CRC biology and into their potential as targets for drug development is warranted.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, fulzerasib (GFH925) / GenFleet Therap
KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC. (Hall B1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1983;
P1/2
The preliminary data from ongoing KROCUS study has demonstrated very promising efficacy and favorable safety profile of fulzerasib + cetuximab in the first line setting of KRAS G12C mutated NSCLC. More data will be generated to provide clinical evidence supporting this combination as a potential frontline therapy.
- Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma. (Hall A; Poster Bd #: 303) - Apr 24, 2024 - Abstract #ASCO2024ASCO_829;
P2
Longer follow-up is required for the accurate assessment of OS. No significant toxicity increases were observed with the addition of UV1.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, ERAS-601 / Erasca
Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma. (Hall A; Poster Bd #: 448) - Apr 24, 2024 - Abstract #ASCO2024ASCO_730;
P1
Encouraging preliminary activity was seen in advanced, refractory chordoma. 1.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: The association of healthcare contact days with physical function and survival in CCTG/AGITG CO.17. (Pubmed Central) - Apr 24, 2024
P3
1. In this secondary analysis of a clinical trial, more contact days early in the course was associated with declines in physical function and worse survival in all-comers and in participants receiving cancer-directed treatment.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small (Pubmed Central) - Apr 23, 2024
In this secondary analysis of a clinical trial, more contact days early in the course was associated with declines in physical function and worse survival in all-comers and in participants receiving cancer-directed treatment. Materials & An ECA for a randomized controlled trial (RCT) in first-line NSCLC was constructed using ConcertAI Patient360
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Cetuximab chemotherapy resistance: Insight into the homeostatic evolution of head and neck cancer (Review). (Pubmed Central) - Apr 23, 2024
The few resistant cells that survive in this new environment obtain differential reproductive success that enables them to pass down the newly selected resistant gene pool. The present review aims to summarize key findings of tumor evolution, epithelial?mesenchymal transition and resistance to cetuximab therapy in head and neck squamous cell carcinoma.
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial, Metastases: Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC (clinicaltrials.gov) - Apr 23, 2024
P1/2, N=26, Recruiting, Sponsor: Wangxia LV
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: LIGHTNING: Real-time Margin Assessment in Head and Neck Cancer (clinicaltrials.gov) - Apr 22, 2024
P2, N=20, Recruiting, Sponsor: University Medical Center Groningen
The present review aims to summarize key findings of tumor evolution, epithelial?mesenchymal transition and resistance to cetuximab therapy in head and neck squamous cell carcinoma. Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Biodistribution and therapeutic efficacy of a gold nanoparticle-based targeted drug delivery system against pancreatic cancer. (Pubmed Central) - Apr 22, 2024
Among the various formulations tested, 5?nm gold nanoparticles coated with gemcitabine, cetuximab and poly-ethylene glycol (PEG) of molecular weight 1000?Da, which we named ACGP441000, demonstrated optimal efficacy in inhibiting tumor growth. The current study reveals an opportunity to target PCCs and PSCs simultaneously, by exploiting their overexpression of EGFR as a target, in order to inhibit pancreatic cancer growth.
- || Avastin (bevacizumab) / Roche
Retrospective data, Review, Journal, Head-to-Head, Metastases: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. (Pubmed Central) - Apr 22, 2024
We evaluated the relative efficacy and safety of first-line EGFRIs plus doublet chemotherapy (FOLFIRI or FOLFOX) vs. bevacizumab plus doublet chemotherapy for patients with RAS WT left-sided mCRC, as well as in all- and right-sided tumors...Safety was available in 6 trials for all-sided tumors and 1 trial for left-sided tumors, each demonstrating typical class-specific adverse events. This most comprehensive meta-analysis indicates a benefit for first-line EGFRI plus chemotherapy over bevacizumab plus chemotherapy in patients with left-sided RAS WT mCRC.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Enrollment open: Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (clinicaltrials.gov) - Apr 22, 2024
P3, N=408, Recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
This most comprehensive meta-analysis indicates a benefit for first-line EGFRI plus chemotherapy over bevacizumab plus chemotherapy in patients with left-sided RAS WT mCRC. Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study. (Pubmed Central) - Apr 19, 2024
The FOLFOXIRI plus cetuximab regimen displayed tolerable toxicity and promising anti-tumor activity in terms of the rate of NED achieved and response rate in patients with initially unresectable left-sided RAS/BRAF wild-type CLM. This regimen merits further investigation.
- | CB-NK-TGF-βR2-/NR3C1 / UT MD Anderson Cancer Center
Trial suspension, Combination therapy, Minimal residual disease: A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) (clinicaltrials.gov) - Apr 19, 2024
P1, N=15, Suspended, Sponsor: M.D. Anderson Cancer Center
This regimen merits further investigation. Recruiting --> Suspended
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Enrollment change, Metastases: Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC (clinicaltrials.gov) - Apr 18, 2024
P2, N=71, Recruiting, Sponsor: University of Wisconsin, Madison
Recruiting --> Suspended N=110 --> 71
- || Review, Journal, PD(L)-1 Biomarker, IO biomarker: Therapeutic Advances and Challenges for the Management of HPV-Associated Oropharyngeal Cancer. (Pubmed Central) - Apr 17, 2024
The most common drugs to treat HPV-associated OPC under these clinical trials and implemented as well for HPV-negative HNC include cisplatin, nivolumab, cetuximab, paclitaxel, pembrolizumab, 5-fluorouracil, and docetaxel...In this context, we identified most mutated genes found in HPV-associated OPC that can represent potential targets for drug development. These include TP53, PIK3CA, PTEN, NOTCH1, RB1, FAT1, FBXW7, HRAS, KRAS, and CDKN2A.
- || MK-1084 / Merck (MSD), Otsuka
Enrollment change, Combination therapy, Monotherapy, Metastases: A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov) - Apr 17, 2024
P1, N=830, Recruiting, Sponsor: Merck Sharp & Dohme LLC
These include TP53, PIK3CA, PTEN, NOTCH1, RB1, FAT1, FBXW7, HRAS, KRAS, and CDKN2A. N=450 --> 830
- | defactinib (VS-6063) / Verastem, Erbitux (cetuximab) / Eli Lilly, EMD Serono, avutometinib (VS-6766) / Verastem
New P2 trial, Combination therapy, Metastases: Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer (clinicaltrials.gov) - Apr 16, 2024
P2, N=33, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- || BI 765063 / Boehringer Ingelheim, BI 836880 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment open, Trial primary completion date, Combination therapy, Metastases: A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (clinicaltrials.gov) - Apr 16, 2024
P1, N=45, Recruiting, Sponsor: Boehringer Ingelheim
N=450 --> 830 Active, not recruiting --> Recruiting | Trial primary completion date: Aug 2024 --> Apr 2025
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Antibody-platinum (IV) prodrugs conjugates for targeted treatment of cutaneous squamous cell carcinoma. (Pubmed Central) - Apr 15, 2024
Cisplatin (CisPt) shows good curative effects; however, its adverse effects and non-tumor-targeting ability are major drawbacks...Specifically, it accurately delivered C8Pt(IV) into tumor cells to exert the combined anti-tumor effect of Cet and CisPt. Herein, metabolomic analysis showed that Cet-C8Pt(IV) promoted cellular apoptosis and increased DNA damage in cSCC cells by affecting the vitamin B6 metabolic pathway in tumor cells, thereby further enhancing the tumor-killing ability and providing a new strategy for clinical cancer treatment using antibody-platinum (IV) prodrugs conjugates.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Cancer stem: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. (Pubmed Central) - Apr 15, 2024
Herein, metabolomic analysis showed that Cet-C8Pt(IV) promoted cellular apoptosis and increased DNA damage in cSCC cells by affecting the vitamin B6 metabolic pathway in tumor cells, thereby further enhancing the tumor-killing ability and providing a new strategy for clinical cancer treatment using antibody-platinum (IV) prodrugs conjugates. AURKA inhibition holds promise as a therapeutic approach to overcome cetuximab resistance in RAS/RAF wild-type colorectal cancer, offering a potential means to counter the development of cancer stem cell phenotypes associated with cetuximab resistance.
- | Journal, Circulating tumor DNA, Metastases: Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial. (Pubmed Central) - Apr 13, 2024
P2
Within the limitation of a subgroup analysis, the absence of liver metastases was associated with significant improved survival. ClinicalTrials.gov Identifiers: NCT02296203; NCT04561336; NCT03227926; NCT05468892.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data, Clinical Trial,Phase II, Journal, Metastases: Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID). (Pubmed Central) - Apr 13, 2024
ClinicalTrials.gov Identifiers: NCT02296203; NCT04561336; NCT03227926; NCT05468892. Our novel treatment strategy delivered acceptable survival outcomes and reduced severe dermatologic toxicities.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Journal, HEOR, Real-world evidence, Real-world: Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC. (Pubmed Central) - Apr 13, 2024
P=N/A
Our novel treatment strategy delivered acceptable survival outcomes and reduced severe dermatologic toxicities. According to the results of our real-life data study, there is no significant difference in efficiency between the combination of biological agent and chemotherapy used in the second-line treatments.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: EGFR-Targeted Antibody-Drug Conjugate to Different Aminobisphosphonates: Direct and Indirect Antitumor Effects on Colorectal Carcinoma Cells. (Pubmed Central) - Apr 13, 2024
Also, the ADCs can trigger the cell proliferation of V?2 T cells present in peripheral blood and tumor specimens. Our findings indicate that anti-EGFR antibodies bound to N-BPs can improve the antitumor effects of the native antibody possibly increasing the therapeutic effect.
- || Krazati (adagrasib) / BMS
Trial completion date, Trial primary completion date, Metastases: Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 (clinicaltrials.gov) - Apr 11, 2024
P1/2, N=822, Recruiting, Sponsor: Mirati Therapeutics Inc.
Our findings indicate that anti-EGFR antibodies bound to N-BPs can improve the antitumor effects of the native antibody possibly increasing the therapeutic effect. Trial completion date: Sep 2024 --> Jan 2026 | Trial primary completion date: Dec 2023 --> Jul 2025
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Tumor mutational burden, Circulating tumor DNA, Metastases: Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment. (Pubmed Central) - Apr 10, 2024
TP53 and AMER1 mutations, tumor mutational burden (TMB) levels, and TP53/AMER1 co-mutation may predict the efficacy of the first-line cetuximab-contained treatment. Situations of genetic mutations were differentiated from first-line PD to second-line PD, which indicated that mutation detection may contribute to predict prognosis of mCRC patients.
- | Erbitux (cetuximab) / Eli Lilly
Trial completion date, Trial primary completion date: Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Apr 8, 2024
P2, N=30, Recruiting, Sponsor: Wake Forest University Health Sciences
Situations of genetic mutations were differentiated from first-line PD to second-line PD, which indicated that mutation detection may contribute to predict prognosis of mCRC patients. Trial completion date: Aug 2024 --> Jan 2025 | Trial primary completion date: Mar 2024 --> Sep 2024
- | Krazati (adagrasib) / BMS, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Metastases: Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. (Pubmed Central) - Apr 8, 2024
Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRASG12C-mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRASG12C mutations in patients with colorectal cancer.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Review, Journal, Metastases: Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions. (Pubmed Central) - Apr 8, 2024
The non-invasive monitoring of molecular resistance to targeted therapies using Next Generation Sequencing analysis of circulating tumor-derived DNA (ctDNA) and captured sequencing of tumors have improved patient selection for targeted therapies. This review will focus on how latest advances, challenges and future directions in the development of targeted therapies in mCRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab decorated redox sensitive D-alpha-tocopheryl- polyethyleneglycol-1000-succinate based nanoparticles for cabazitaxel delivery: Formulation, lung targeting and enhanced anti-cancer effects. (Pubmed Central) - Apr 8, 2024
In addition, the in-vitro cellular uptake investigation showed that CTX-TPGS-SS-CMN6-NPs accumulated significantly compared to pure CMN6, TPGS-CMN6-NPs, and TPGS-SS-CMN6-NPs in the A549 cells. Furthermore, the targeting efficiency of developed NPs were analysed by ultrasound/photoacoustic and IVIS imaging.
- | Visudyne (verteporfin) / Novartis
Journal: Verteporfin fluorescence in antineoplastic-treated pancreatic cancer cells found concentrated in mitochondria. (Pubmed Central) - Apr 5, 2024
In GEM -treated human PC cells, verteporfin was particularly prevalent in the mitochondria. This study supports further study of PDT for the treatment of PC after neoadjuvant chemotherapy.
- || BND-22 / Biond Biologics, Sanofi
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 4, 2024
P1/2, N=456, Recruiting, Sponsor: Sanofi
This study supports further study of PDT for the treatment of PC after neoadjuvant chemotherapy. Trial completion date: Apr 2027 --> Nov 2026 | Trial primary completion date: Apr 2027 --> Nov 2026
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Combination therapy, Surgery, Metastases: Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 4, 2024
P1/2, N=23, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- || PF-07284892 / Pfizer
Enrollment change, Combination therapy, Metastases: PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 4, 2024
P1, N=53, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Apr 2027 --> Nov 2026 | Trial primary completion date: Apr 2027 --> Nov 2026 N=36 --> 53
- ||| D3S-001 / D3 Bio
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation (clinicaltrials.gov) - Apr 4, 2024
P1/2, N=352, Recruiting, Sponsor: D3 Bio (Wuxi) Co., Ltd
N=36 --> 53 Phase classification: P1 --> P1/2 | N=168 --> 352 | Trial completion date: May 2025 --> Sep 2026 | Trial primary completion date: May 2025 --> Sep 2026
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: NuTide:302: A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment (clinicaltrials.gov) - Apr 3, 2024
P1/2, N=107, Completed, Sponsor: NuCana plc
Phase classification: P1 --> P1/2 | N=168 --> 352 | Trial completion date: May 2025 --> Sep 2026 | Trial primary completion date: May 2025 --> Sep 2026 Recruiting --> Completed | N=225 --> 107 | Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Nov 2023 --> Mar 2024
- ||| Krazati (adagrasib) / BMS, Erbitux (cetuximab) / Eli Lilly, EMD Serono, BMS-986466 / BMS
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors (clinicaltrials.gov) - Apr 3, 2024
P1/2, N=410, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | N=225 --> 107 | Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Nov 2023 --> Mar 2024 Recruiting --> Active, not recruiting | Trial completion date: Jul 2029 --> May 2024 | Trial primary completion date: Aug 2027 --> May 2024
- || Review, Journal: Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver. (Pubmed Central) - Apr 1, 2024
Other combinations such as adagrasib-cetuximab, divarasib-cetuximab, or FOLFIRI-panitumumab-sotorasib have also shown a meaningful response rate and are currently under evaluation...In this setting, liquid biopsy emerges as a critical tool to characterize the mechanisms of resistance, consisting mainly of acquired genomic alterations in the MAPK and PI3K pathways and tyrosine kinase receptor alterations, but gene fusions, histological changes, or conformational changes in the kinase have also been described. In this paper, we review the development of KRAS G12C inhibitors in colorectal cancer as well as the main mechanisms of resistance.